<DOC>
	<DOCNO>NCT02059161</DOCNO>
	<brief_summary>The purpose study compare safety efficacy MK-1293 Lantus™ participant T1DM . The primary hypothesis 24 week , mean change hemoglobin A1c ( A1C ) baseline non-inferior participant treat MK-1293 compare participant treat Lantus™ .</brief_summary>
	<brief_title>A Study Safety Efficacy MK-1293 Compared Lantus™ Participants With Type 1 Diabetes Mellitus ( T1DM ) ( MK-1293-003 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>T1DM For least 1 year currently use use prandial insulin least 4 week . Participants take type basal insulin require total daily dose &gt; =10 units/day . For participant currently take premixed insulin , basal insulin component equivalent total daily dose &gt; =10 units/day . male , female reproductive potential reproductive potential agrees remain abstinent use ( partner use ) acceptable method birth control study 14 day last dose study medication 1 severe hypoglycemic episode associate hypoglycemic seizure loss consciousness within past 6 month history ketoacidosis last 6 month participant , assessed investigator , appropriate agree target fast glucose 70100 mg/dL [ 3.9 5.6 mmol/L ] . history intolerance hypersensitivity Lantus™ contraindication Lantus™ one excipients use formulation insulin glargine Lantus™ receive injectable incretinbased therapy within past 8 week weight loss program maintenance phase , start weight loss medication within past 8 week undergone bariatric surgery within past 12 month likely require treatment 2 consecutive week repeat course corticosteroid ( note : inhale , nasal , topical corticosteroid permit ) undergone surgical procedure within past 4 week plan major surgery study new worsen sign symptom coronary heart disease congestive heart failure within past 3 month , follow disorder within past 3 month : acute coronary syndrome , coronary artery intervention , stroke transient ischemic neurological disorder severe peripheral vascular disease high blood pressure chronic myopathy , progressive neurological neuromuscular disorder active nephropathy history active liver disease ( nonalcoholic hepatic steatosis ) , include chronic active hepatitis B C , primary biliary cirrhosis , symptomatic gallbladder disease human immunodeficiency virus ( HIV ) hematological disorder ( aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) history malignancy past 5 year , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer history melanoma , leukemia , lymphoma , renal cell carcinoma currently treat hyperthyroidism stable dose thyroid hormone replacement therapy &lt; 6 week user recreational illicit drug recent history drug alcohol abuse dependence pregnant breastfeeding , expect conceive donate egg donate blood product phlebotomy &gt; 300 mL within past 8 week intend donate blood product study poor mental function work night shift</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>